profitmaker schreef op 16 april 2015 09:40:
Zie onderstaand bericht. Reden dat ik ATHX gisteren heb ingeslagen komt door de forse daling die zich gisteren voordeed en in geen verhouding staat tot de afgelopen 10 handelsdagen (koers onterecht dus ineens zo hard gezakt naar mijn mening). Daarnaast zal de presentatie die aanstaande zondag in Schotland volgt de koers maandag en dinsdag volgende week weer boven de 3 dollar duwen verwacht ik. Doe je eigen analyse maar ATHX nu kopen op huidige koers van 2,65 is zeer interessant vermoed ik.
Artikel:
Athersys Phase 2 Ischemic Stroke Clinical Trial Results to be Presented at European Stroke Conference
Dr. David Hess to Present the Preliminary Results
CLEVELAND, April 8, 2015 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that Dr. David Hess, a stroke specialist and Chairman of the Department of Neurology at the Medical College of Georgia Regents University, and the lead principal investigator in the study, will present the preliminary results from its Phase 2 clinical trial administering MultiStem® for the treatment of ischemic stroke. The presentation will take place at the European Stroke Organization Conference (ESOC) 2015 on Sunday, April 19th starting at 8:50 am in Glasgow, Scotland, United Kingdom. Dr. Hess' presentation will be in the Boisdale Room of the Scottish Exhibition and Conference Centre in Glasgow, in the conference venue.
Athersys' double-blind, placebo-controlled Phase 2 clinical trial is being conducted at leading stroke centers across the United States and in the United Kingdom to evaluate the safety and efficacy of its proprietary MultiStem cell therapy in adults who have suffered a severe ischemic stroke and are treated 24-48 hours following the stroke. Dr. Hess served as the lead clinician for the Phase 2 clinical trial, which also included clinical research teams from Oregon Health Sciences University, Houston Methodist Hospital, University of Pittsburgh Medical Center, Cleveland Clinic, Newcastle Upon Tyne and Stoke on Trent, among others. Trial enrollment was completed in December 2014 and this will be the first presentation of the unblinded results.